The Oncology Care Model (OCM) is scheduled to end in just a few months, but with no new model in place to succeed it and practices still struggling during the pandemic, CMS should allow OCM to continue, said Kashyap Patel, MD, a co-chair of Patient-Centered Oncology Care® and the current president of the Community Oncology Alliance. He is CEO of Carolina Blood and Cancer Care Associates.
The OCM is getting close to the end, but the country is still in the midst of a pandemic. What shoudl the next step be?
PATEL: OCM has been, in my opinion, a successful program in at least changing patient experience and helping practices [develop] true patient-centered care. Of course, some of the practices have not been able to achieve the fi nancial targets for savings. But in my opinion, OCM has given us a blueprint for what the future of cancer care looks like. And until the pandemic is over, the OCM should continue in its current form, because practices are heavily invested in this practice transformation.
The future model should actually [take] social and economic disparities [into account]. We were not aware of the impact of disparities, [but] if you look at the 2020 American Association of Cancer Research (AACR) report, it clearly highlights that there is a 34% higher risk of death for patients who are exposed to disparities.
Between 2003 and 200, we ended up spending $230 billion more in direct care and almost $1 trillion in indirect expenses. So, economically, socially, morally, and just system-wise, we need to factor in the social disparities as well as economic disparities in designing any future model that will be truly successful in helping deliver patient-centered care.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302
February 15th 2025The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered an achievement; in this study, median overall survival was 34 months after treatment with enfortumab vedotin (EV) and pembrolizumab (pembro).
Read More
Analysis Looks at Benefits, Toxicity of ADC Combinations in Advanced Bladder Cancer
February 15th 2025City of Hope's Salvador Jaime-Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody-drug conjugate (ADC) combinations in advanced urothelial cancer.
Read More